Vogel Heerma Waitz advises Captain T Cell on seed financing round

Berlin — Captain T Cell GmbH, a biotech­no­logy company deve­lo­ping next-gene­ra­­tion T cells against solid tumors, has successfully closed a seed finan­cing round of 8.5 million euros. A consor­tium of expe­ri­en­ced life science inves­tors, inclu­ding i&i Biotech Fund I SCSp, Bran­den­burg Kapi­tal GmbH and HIL-INVENT Ges.m.b.H, parti­ci­pa­ted in the round.

In addi­tion, the Fede­ral Minis­try of Educa­tion and Rese­arch (BMBF) supports the company through its renow­ned GO-Bio program. The finan­cing also marks the appoint­ment of biotech vete­ran Jörn Aldag as Chair­man of the Advi­sory Board. — Dr. Lorenz Frey and Dr. Frank Vogel from the law firm Vogel Heerma Waitz advi­sed Captain T Cell.

The capi­tal from the seed finan­cing round will be used to bring a new gene­ra­tion of T‑cell thera­pies against solid tumors into the clinic.

Captain T Cell is deve­lo­ping TCR‑T cells with increased effi­cacy for solid tumors that cannot be trea­ted with exis­ting thera­pies. Using a series of novel tech­no­lo­gies, Captain T Cell gene­ra­tes TCR‑T cells with increased persis­tence and the ability to effec­tively coun­ter­act the hostile tumor microen­vi­ron­ment of diffi­­cult-to-treat solid tumors. In precli­ni­cal in vivo models, the company has succee­ded in comple­tely rejec­ting aggres­sive tumors with these effi­­cacy-enhan­­ced T cells. A key tech­no­logy deve­lo­ped by the Captain T Cell team is the company’s proprie­tary TCR-ALLO plat­form for off-the-shelf treat­ment of solid tumors. The TCR-ALLO plat­form is a univer­sal tool that can be exten­ded to a variety of cancer indications.

The company is a spin-off of the renow­ned Max Delbrück Center in Berlin, Germany, a leading Euro­pean biome­di­cal rese­arch insti­tu­tion. The Insti­tute provi­ded valuable finan­cial and infra­struc­tu­ral support during the pre-seed phase and, toge­ther with its tech­no­logy trans­fer part­ner Ascen­ion, remains a close part­ner for future ventures.

Captain T Cell is based in Schönefeld/Berlin and is supported by the expe­ri­en­ced Euro­pean inves­tors i&i Biotech Fund I SCSp, Bran­den­burg Kapi­tal GmbH and HIL-INVENT Ges.m.b.H.. Captain T Cell was foun­ded by an ambi­tious team of immuno-onco­­logy experts. The tech­no­lo­gies were deve­lo­ped at the Max Delbrück Center for Mole­cu­lar Medi­cine in the Helm­holtz Asso­cia­tion in Berlin. www.captaintcell.com

Consul­tant: Vogel Heerma Waitz

Dr. Lorenz Frey, Dr. Frank Vogel

About Vogel Heerma Waitz

Vogel Heerma Waitz is a Berlin-based law firm specia­li­zing in growth capi­tal, tech­no­logy and media.